

impedimed

ASX ANNOUNCEMENT

Mayo Clinic to use SOZO™ in Heart Failure Study

Brisbane, Australia and Carlsbad, Calif. 18 October, 2016 - ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that Mayo Clinic together with Atlantic Health System will use the SOZO™ device in a feasibility study for monitoring patients with heart failure. The study will provide real-world data necessary for the final design of the pivotal trial.

The study is being led by Dr. Roy Small, Medical Director of Clinical Research, Lancaster General Hospital. Scripps Health and Harvard Clinical Research Institute are collaborators on the study. Dr. Small is a member of ImpediMed's Medical Advisory Board.

Patients in the study will be recruited at Mayo Clinic in Rochester and Atlantic Health System in New Jersey.

Mr. Richard Carreon, ImpediMed's Managing Director and CEO, stated, "We are pleased that such prestigious clinicians and cardiovascular institutions have partnered with us to study the potential impact our technology may have for chronic heart failure patients."

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contacts:

In Australia:

Kyahn Williamson, Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

In the US:

Patti Hixon, Jones-Dilworth, Inc.
T: +1 512.633.1263
E: patti@jones-dilworth.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. For more information, visit www.impedimed.com.

For personal use only